Praxis precision medicines to present at h.c. wainwright 24th annual global investment conference

Boston, sept. 07, 2022 (globe newswire) -- praxis precision medicines, inc. (nasdaq: prax), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (cns) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside chat at the h.c. wainwright 24th annual global investment conference on wednesday, september 14, 2022 at 10:30 a.m. et.
PRAX Ratings Summary
PRAX Quant Ranking